Dear Reader,

Welcome to the final issue of Pharmaceutical Medicine for 2022.

As we reach the end of another successful year, I would like to thank all those who have contributed their valuable time and effort to the journal over the past 12 months.

The Section Editors and I would like to begin by thanking the authors who have contributed articles to Pharmaceutical Medicine over the course of 2022. The skill and dedication of these experts is critical to the continued success of the journal.

The quality of published articles is also testament to the significant efforts of the peer reviewers, whose commitment ensures that the journal’s content is held to the highest possible standard. We would therefore like to thank the following individuals who acted as reviewers for Pharmaceutical Medicine in the last 12 months:

Mohamed Abou-el-Enein, USA

Lisbeth Barkholt, Sweden

Andrew Bate, UK

Saleh A. Bawazir, Saudi Arabia

Alexander Bedenkov, UK

Shachi Bista, Sweden

Marc Buyse, Belgium

Brent Ower Caldwell, New Zealand

Orin Chisholm, Australia

Lesong Conteh, UK

Chelsie W.W. Counsell, USA

Douglas Coyle, Canada

Saskia de Morée, Canada

Guy S. Diamond, USA

Isabelle S. Durand-Zaleski, France

Brian David Edwards, UK

Vicki Edwards, UK

Simon Erridge, UK

Ana Fraguas-Sanchez, Spain

Louis Preston Garrison Jr, USA

Monalisa Ghosh, USA

Henry G. Grabowski, USA

Stephen Groft, USA

Sarah Hall, UK

Jill Harkavy-Friedman, USA

Brett Hauber, USA

Cecilia J. Hillard, USA

Carsten Hjorthøj, Denmark

Alan M. Hochberg, Switzerland

Thomas J. Hwang, USA

Liza-Marie Johnson, USA

Seetharama Jois, USA

Sigal Kaplan, Israel

Ronald Kiguba, Uganda

Marie-Laure Kürzinger, France

Samantha Lane, UK

Paul Lartey, USA

Catherine Y. Lau, Canada

Sharon B. Love, UK

Murray Lumpkin, USA

Tamra Lysaght, Singapore

Terri Madison, USA

Hideki Maeda, Japan

Jonathan Mahnken, USA

Olivia Mahaux, Belgium

David Morgan, UK

Monica A. Muñoz, USA

Carl Naraynassamy, UK

Koji Oba, Japan

Olga Ostrovsky, USA

Steve Pascolo, Switzerland

Siddharth Patel, USA

Raffaella Ravinetto, Belgium

Frances J. Richmond, USA

David B. Ridley, USA

Paul D. Robbins, USA

Bruno Rodrigue, Canada

Kaye Rolls, Australia

Jakob Daniel Rudzki, Austria

Andreas Seiter, USA

Meredith Yearsley, Smith, USA

Julia Spoendlin, Switzerland

Thomas Sudhop, Germany

Maw Pin Tan, Malaysia

Philippe Thomas, Germany

Christopher J. Twelves, UK

Kristel Van de Voorde, Belgium

Sibren van den Berg, The Netherlands

Jan Van Parijs, Belgium

Robert Vander Stichele, Belgium

Katarina Vucic, Croatia

Timothy E. Welty, USA

Ruth Wood, UK

Michael Zaiac, Switzerland

Yi Zhu, USA

Inge M. Zomerdijk, The Netherlands

Through the hard work of our authors and reviewers, we continue to see great gains in article usage. The most popular 2022 articles to date, in terms of downloads from SpringerLink, are:

•Digital Transformation in Medical Affairs Sparked by the Pandemic: Insights and Learnings from COVID-19 Era and Beyond. 36(1):1–10. https://doi.org/10.1007/s40290-021-00412-w

•Delivery Strategies for mRNA Vaccines. 36(1):11–20. https://doi.org/10.1007/s40290-021-00417-5

•Medical Affairs Transformation in Specialty Pharma: Next-Level Collaboration at the Core. 36(2):63–69. https://doi.org/10.1007/s40290-022-00419-x

•Cannabidiol and Other Phytocannabinoids as Cancer Therapeutics. 36(2):99–129. https://doi.org/10.1007/s40290-022-00420-4

•Barriers to Chimeric Antigen Receptor T-Cell (CAR-T) Therapies in Clinical Practice. 36(3):163–171. https://doi.org/10.1007/s40290-022-00428-w

•Dispositions and Causality Assessment in Pharmacovigilance: Proposing the Dx3 Approach for Assessing Causality with Small Data Sets. 36(3):153–161. https://doi.org/10.1007/s40290-022-00429-9

•The Carbon Costs of In-Person Versus Virtual Medical Conferences for the Pharmaceutical Industry: Lessons from the Coronavirus Pandemic. 36(2):131–142. https://doi.org/10.1007/s40290-022-00421-3

•Impact of Changing Regulations and the Dynamic Nature of European Risk Management Plans for Human Medicines on the Lifecycle of Safety Concerns. 36(1):33–46. https://doi.org/10.1007/s40290-021-00414-8

•Development and Validation of the Medical Affairs Pharmaceutical Physician Value (MAPPval) Instrument. 36(1):47–57. https://doi.org/10.1007/s40290-021-00413-9

•Digital Additional Risk Minimization Measures: An Exploratory Study Using Qualitative Feedback from Healthcare Professionals and Patients Across Six Countries. 36(1):21–32. https://doi.org/10.1007/s40290-021-00415-7

We gratefully acknowledge all of the members of the journal’s Honorary Editorial Board, who have acted as peer reviewers and authors, and have provided guidance on journal content, policy and processes:

Dr Peter R. Arlett, MD MRCP. European Medicines Agency, Amsterdam, The Netherlands

Dr Sander Becker, MD. Consultants in Pharmaceutical Medicine, Rose Bay North, NSW, Australia

Dr Ambrogio Bottoni, MD. Pfizer Inc., Milan, Italy

Dr Torbjӧrn Callréus, MD PhD. Malta Medicines Authority, San Ġwann, Malta

Dr Norbert Clemens, MD PhD CPI. Association of Clinical Research Professionals Academy Board of Trustees, Heidelberg, Germany

Mr Francis P. Crawley, PhL. Good Clinical Practice Alliance – Europe, Brussels, Belgium

Dr Jean-Paul Deslypere, MD PhD. Council on Education in Pharmaceutical Medicine, Singapore

Dr Francesco De Tomasi, MD. Italian Society of Pharmaceutical Medicine, Milan, Italy

Dr Georg Ferber, PhD. Statistik Georg Ferber GmbH, Riehen, Switzerland

Professor Anthony W. Fox, MSc MBBS MD FFPM FRCP DipPharmMed MCSFS DipFHI MFMLM CBiol. The Inns of Court College of Advocacy, London, England

Dr Claudio Fracasso, MD. Pfizer S.r.l., Rome, Italy

Professor Sanjay K. Garg, PhD. University of South Australia, Adelaide, SA, Australia

Dr E. Stewart Geary, MD. Eisai Co. Ltd., Tokyo, Japan

Mr Kenneth A. Getz, MBA. Tufts University Medical School, Boston, MA, USA

Mr Ari Gnanasakthy, BSc MSc MBA. RTI Health Solutions, Research Triangle Park, NC, USA

Dr Ulrich Granzer, PhD. Granzer Regulatory Consulting & Services, Munich, Germany

Professor Jan D. Hirsch, BSPharm PhD. University of California, Irvine, CA, USA

Mr Alan Hunter, LLB BPharm, FPS, FTOPRA. Independent Pharmaco-Legal Adviser, Staines, England

Dr Ambrose O. Isah, MD. University of Benin, Benin, Nigeria, Africa

Dr Greg Koski, MD PhD CPI. Alliance for Clinical Research Excellence and Safety, Cambridge, MA, USA

Dr Marlene Llopíz Avíles, BA MD MPH. Association of Medical Specialists in the Pharmaceutical Industry, Mexico City, Mexico

Dr Marcelo Marotti, MD PhD. AstraZeneca UK Ltd., Macclesfield, England

Dr Peter G. M. Mol, PhD, PharmD. Dutch Medicines Evaluation Board, Utrecht, The Netherlands

Dr Shunsuke Ono, PhD. University of Tokyo, Tokyo, Japan

Dr María Proupín-Pérez, PhD. CSL Behring Innovation GmbH, Marburg, Germany

Professor Sir Michael Rawlins, BSc MD FRCP FFPM. Medicines and Healthcare Products Regulatory Agency, London, England

Dr Klaus Rose, MD MS. Klausrose Consulting, Riehen, Switzerland

Professor Sam Salek, BPharm PhD RPh MRPSGB FFPM FESCP. University of Hertfordshire, Hatfield, England

Professor Grannum R. Sant, MD FRCS FACS. Tufts University School of Medicine, Boston, MA, USA

Dr Ruth Savage, MB BS MSc. University of Otago, Dunedin, New Zealand

Dr Jeffrey W. Sherman, MD FACP. Horizon Pharma, Deerfield, IL, USA

Dr Honorio Silva, MD. International Federation of Associations of Pharmaceutical Physicians and Pharmaceutical Medicine, New York, NY, USA

Dr Noel Snell, FRCP FFPM FRIPH FIBiol. National Heart & Lung Institute, London, England

Professor Peter D. Stonier, BA BSc PhD MB ChB MRCPsych FRCP FRCPE FFPM. King’s College London, London, England

Dr Robert Temple, MD. Center for Drug Evaluation & Research, Food and Drug Administration, Rockville, MD, USA

Professor Rolf Teschke, MD. Klinikum Hanau, Hanau, Germany

Professor Stuart R. Walker, BSc PhD CChem CBiol FRSC FIBiol FInstD FRCPath. Centre for Innovation in Regulatory Science, Carshalton, England

We hope that you have found the articles published throughout 2022 to be both interesting and informative. The editors have appreciated the high quality of content contributed to the journal this year and look forward to keeping you up to date with topical issues in the pharmaceutical medicine field in 2023, when the journal will also receive its first Impact Factor.

With best wishes from the Editor and staff of Pharmaceutical Medicine.

Sue Pochon